1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Latuda (Schizophrenia) - Forecast and Market Analysis to 2022

  • February 2014
  • 39 pages
  • GlobalData
Report ID: 2081692

Summary

Table of Contents

Latuda (Schizophrenia) - Forecast and Market Analysis to 2022

Summary

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Latuda is a mixed D2/5-HT2A receptor antagonist with additional activity on 5-HT7 receptors. Unlike Fanapt, Latuda does not act on muscarinic or histaminergic receptors, and is thus associated with lower risks of weight gain and metabolic disturbances. Latuda is promoted as a drug that is pro-cognitive in nature and may help to relieve some of the cognitive deficits in schizophrenic patients.

Scope

- Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Latuda including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Latuda for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Latuda performance
- Obtain sales forecast for Latuda from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Chronic Obstructive Pulmonary Disease - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • May 2017
  • by GlobalData

PharmaPoint: Chronic Obstructive Pulmonary Disease - Global Drug Forecast and Market Analysis to 2025 Summary COPD is a progressive lung disease characterized by an abnormal inflammatory response and airflow ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2026

  • $ 10995
  • Industry report
  • June 2017
  • by GlobalData

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2026 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2026

  • $ 10995
  • Industry report
  • September 2017
  • by GlobalData

GlobalData estimates sales of HF therapeutics to be approximately $3.7B across the 7MM in 2016, encompassing the US, the five major European markets (5EU: France, Germany, Italy, Spain and UK), and Japan. ...

Nash: Kol Insight [2017]

June 2017 $ 9015

Car-t Disease Outlook [2017]

June 2017 $ 8355

Download Unlimited Documents from Trusted Public Sources

Therapy Market

  • September 2017
    12 pages
  • Therapy  

    Therapy  

View report >

Diabetes Statistics

  • September 2017
    10 pages
  • Diabetes  

    Therapy  

View report >

Vaccine Market and Influenza Statistics in India

  • September 2017
    6 pages
  • Vaccine  

    Influenza  

    Diabetes  

  • India  

    United States  

View report >

Related Market Segments :

Therapy
Psychotic Disorder

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.